Top news of the week: 17.02.2023.
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced ...
Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment ...
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
Previously Announced Phase 2 Clinical Trials Initiated in Minimal Change Disease and Sjögren‑Larsson SyndromePhase 2 Clinical Trial in Minimal Change Disease Expanded to Encompass ...
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2022
Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, provides an update on ...
TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen Humanity Hospital in China.FOOTHILL RANCH, Calif.--(BUSINESS ...
Replay partners with MD Anderson’s Katy Rezvani, heads to clinic with new TCR NK cell company
Hub-and-spoke company Replay has launched a new cell therapy company called Syena, co-founded by NK cell leader Katy Rezvani of the University of Texas MD Anderson Cancer Center. Syena ...
Inside Precision Medicine February 2023: Page 1
Menu Advertisers Feed Facebook FEBRUARY 2023 Real-World Evidence propels Precision Medicine Forward Epigenetic Explorations AI-Powered Radiology A New Frontier of Protein …
Spain's Grifols to dismiss more than 2,000 US employees in $427M cost savings bid
Many biotechs and pharmas have had to pull out the budget axe in a bid to cut costs this year — and now a major Spanish company is joining their ranks. The pharma and blood and plasma giant ...